ClinicalTrials.gg
Status unknownNCT03441607OAUpdated Sep 28, 2018

Safety & Efficacy FloGraft (Micronized Human Amnion Chorion Membrane)® in Adults With Pain Due to OA of the Knee

A Phase 2 interventional study of mHACMb and placebo in Osteoarthritis, Knee, sponsored by Applied Biologics, LLC. Status unknown at 1 site in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2018-09-28.

Sponsored by Applied Biologics, LLC · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Study summary

Safety \& Efficacy of FloGraft (Micronized Human Amnion Chorion Membrane)® in Adults With Pain Due to Osteoarthritis of the Knee.

02

Conditions studied

  • Osteoarthritis, Knee
03

In context

Osteoarthritis, Knee

3,292 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's planned enrollment of 320 is above the median of 68 across 2,714 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Applied Biologics, LLC is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written to participate in the study.
  • Willing and able to participate in all procedures and follow-up evaluations necessary to complete the study.
  • Subject is 30 years or older.
  • Moderate OA pain (rating of at least 20mm on the VAS) assessed at Baseline.
  • Moderate to moderately-severe OA pain in the index knee (rating of at least 1.5 on the WOMAC Index 3.1 5-point Likert Pain Subscale) assessed at Baseline.
  • Must be ambulatory.
  • No analgesia (including acetaminophen [paracetamol]) taken 12 hours prior to an efficacy measure.

Exclusion criteria

Exclusion Criteria:

  • Subject has active infection at the injection site.
  • Subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any other auto-immune disorders that could be the cause of their knee pain.
  • greater than 40 kg/m2.
  • Subject has received an intra-articular hyaluronic acid (HA) injection for the treatment of OA of the target knee within 3 months prior to screening.
  • Subject has received an intra-articular amniotic fluid, amniotic membrane or amniotic fluid/membrane combination injection for the treatment of OA of the target knee within 3 months prior to screening.
  • Subject has received a , bone marrow aspirate concentrate (BMAC) or rich plasma (PRP) injection for the treatment of OA of the target knee within 3 months prior to screening.
  • Subject has had major surgery, arthroplasty or arthroscopy in the target knee within 26 weeks of treatment or plans to have surgery in the target knee within 180 days of treatment.
  • Subject is pregnant or plans to become pregnant within 180 days of treatment.
  • Subject has used an drug, device or biologic within 12 weeks prior to treatment.
  • Subject has any significant medical condition that, in the opinion of the Investigator, would interfere with protocol evaluation and participation.
  • Subject is currently taking anticoagulant therapy (excluding Plavix or Aspirin).
  • Diagnosis of gout in the past 6 month.
  • Major injury to the target knee within the 12 months prior to the screening.
  • Severe hip osteoarthritis ipsilateral to the target knee.
  • Any pain that could interfere with the assessment of the target knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Active comparator
    Drug

    Intervention: 40 mg of micronized human amnion chorion membrane biologic (mHACMb); administered 1(x) on second visit; followed by 2 follow-up visits for assessment over a duration of 3 months.

    Drug: mHACMb

  • Placebo comparator
    Placebo

    Intervention: 1cc of saline will be administered as a one time injection on visit 2, administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.

    Other: placebo

Interventions

  • DrugmHACMb

    Active ingredient

    Also known as: 40mg FloGraft (micronized human amnion chorion membrane)®, 100mg FloGraft (micronized human amnion chorion membrane)®

  • Otherplacebo

    inactive ingredient

    Also known as: saline

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale (VAS)

    Decreased Pain Level

    Time frame: 3 Months

Secondary outcomes

  1. Western Ontario and McMaster Universities Arthritis Index (WOMAC®) osteoarthritis Index 3.1.

    Decrease in pain, stiffness, and physical functioning of the joints.

    Time frame: 3 Months

07

Study locations

1 site
  • Texas Orthopedic Hospital
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03441607
Lead sponsor
Applied Biologics, LLC
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Nov 2018 (estimated)
Primary completion
Feb 2019 (estimated)
Completion
Mar 2019 (estimated)
Last update
Sep 28, 2018

Study contacts

Samantha Montgomery
Contact
samantha.montgomery@appliedbiologics.com
602-325-1221 ext. 9825
Edward Britt
study director · Applied Biologics, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion